StockData
Xtant Medical Holdings, Inc. logo

Xtant Medical Holdings, Inc. (XTNT) stock

XTNTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 9/3074% below fair value
$0.28−0.00 (-0.94%)

Close on Nov 12, 2026Market cap $38.62MP/E –Yield –

Earnings

Xtant Medical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 9, 2026
Q3 FY2026 · estimated, during market hours
Revenue, Q2 FY2026
$23.00M
-35.0% on a year earlier
EPS, Q2 FY2026
-$0.07
$0.02 a year earlier
Latest guidance
Lowered
Aug 11, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Xtant Medical's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 9, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 11, 2026before the open$23.00M-35.0%-$0.07Release
Q1 FY2026ended Mar 31, 2026May 13, 2026before the open$20.90M-36.5%-$0.02Release
Q4 FY2025ended Dec 31, 2025Mar 31, 2026before the open$32.40M+2.9%$0.00Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025during market hours$33.30M+19.4%$0.01Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025before the open$35.40M+18.4%$0.02Release
Q1 FY2025ended Mar 31, 2025May 12, 2025during market hours$32.90M+17.9%$0.00Release
Q4 FY2024ended Dec 31, 2024Mar 6, 2025during market hours$31.50M–-$0.02Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024during market hours$27.90M+11.6%-$0.04Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open$29.90M–-$0.03Release
Q1 FY2024ended Mar 31, 2024May 15, 2024during market hours$27.90M+55.9%-$0.03Release
Q3 FY2023ended Sep 30, 2023Nov 9, 2023before the open$25.00M+72.4%$0.07Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Xtant Medical's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
full-year guidanceFY2026$99.00M – $103.00M$101.00M – $105.00MLoweredAug 11, 2026

Guidance vs results

The last range Xtant Medical gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$131.00M – $135.00M$134.00MΣ4QWithin range
FY2025Revenue growth+11% – +15%+14.33%Σ4QWithin range
Q1 FY2025Revenue$32.80M – $33.10M$32.90MWithin range
Q1 FY2025Revenue growth+18% – +19%+17.92%Below range

Guidance history

Every forecast Xtant Medical put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 11, 2026full-year guidanceFY2026$99.00M – $103.00MLowered
May 13, 2026revenue guidanceFY2026$101.00M – $105.00MRaised
Mar 31, 2026revenueFY2026$95.00M – $99.00MNew
Nov 10, 2025growth over the Company’s full-year 2024 revenueFY2025+11% – +15%New
Nov 10, 2025revenue guidanceFY2025$131.00M – $135.00MNew
Aug 12, 2025growth over the Company’s 2024 revenueFY2025+11% – +15%Raised
Aug 12, 2025full-year 2025 revenue guidanceFY2025$131.00M – $135.00MRaised
May 12, 2025revenue guidanceFY2025$127.00M – $131.00MRaised
Apr 16, 2025growth compared to first quarter 2024 revenueQ1 FY2025+18% – +19%New
Apr 16, 2025revenueQ1 FY2025$32.80M – $33.10MNew
Mar 6, 2025organic growthFY2025+7% – +11%New
Mar 6, 2025revenueFY2025$126.00M – $130.00MNew
Nov 12, 2024annual growthFY2024+27% – +31%New
Nov 12, 2024revenueFY2024$116.00M – $120.00MReaffirmed
Aug 8, 2024revenueFY2024$116.00M – $120.00MReaffirmed
May 15, 2024revenueFY2024$116.00M – $120.00MNew
Nov 9, 2023revenueFY2023$88.00M – $91.00MRaised
May 4, 2023revenueFY2023$73.00M – $75.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Xtant Medical filed with the SEC as exhibits to Form 8-K or 6-K

  1. Medical Reports Second Quarter 2026 Financial Results
    Results
  2. Medical Reports First Quarter 2026 Financial Results
    Results
  3. Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon’s HEMOBLAST® Bellows Product
    Update
  4. Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
    Results
  5. PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
    Update
  6. Medical Completes Sale of its Coflex ® Assets and
    Update
  7. Medical Reports Third Quarter 2025 Financial Results
    Results
  8. Medical Reports Second Quarter 2025 Financial Results
    Results
  9. Quarterly results release
    Results
  10. Medical Announces Definitive Agreements for the Sale of its Coflex ® and CoFix ® Spinal Implants and All
    Update
  11. Medical Reports First Quarter 2025 Financial Results
    Results
  12. Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue
    Results
  13. Xtant Medical Reports Fourth Quarter and Full Year
    Results
  14. Medical Reports Third Quarter 2024 Financial Results
    Results
  15. (Unaudited, in thousands, except share data)
    News

See a number that looks wrong?